PD-L1 bispecific CARs + CXCL10 armored CARs

PD-L1 bispecific CARs + CXCL10 armored CARs is an experimental cell-based immunotherapy designed for the treatment of diffuse midline gliomas (DMGs), which are aggressive and fatal brainstem tumors in children and adolescents. The therapy utilizes CAR T cells engineered to target the B7-H3 (CD276) antigen. These CAR T cells are further modified to secrete two functional components: a bispecific T cell engager (BiTE) that targets PD-L1 on tumor cells and CD3 on T cells, and the chemokine CXCL10. The BiTE is intended to convert the tumor's PD-L1-mediated immune defense into a vulnerability by creating an immune synapse, while CXCL10 serves to recruit endogenous immune cells into the tumor microenvironment to assist in tumor eradication. This multi-pronged approach aims to overcome the immunosuppressive nature of DMGs and enhance the effectiveness of the CAR T-cell therapy.

Other names

B7-H3-directed CAR T cells secreting PD-L1 x CD3 BiTE and CXCL10B-7-H3-directed CAR T cells secreting PD-L1 x CD3 BiTE and CXCL10B 7-H3-directed CAR T cells secreting PD-L1 x CD3 BiTE and CXCL10